Use of pramipexole or a salt thereof for the treatment of parkinson's disease
AssigneeBoehringer Ingelheim International GmbH
InventorsJeffrey G. Huth, Elizabeth Keating
Life of this patent
Estimating the term…
Abstract
The present invention refers to the use of pramipexole, pramipexole hydrochloride, pramipexole dihydrochloride or pramipexole dihydrochloride monohydrate for the manufacture of a medicament for the treatment of early Parkinson's disease by a maintenance, twice daily application.
Claims23
A method for treating early Parkinson's disease in a patient, comprising administering to said patient an effective amount of an immediate release formulation containing an active ingredient selected from the group consisting of pramipexole, pramipexole hydrochloride, pramipexole dihydrochloride and pramipexole dihydrochloride monohydrate, or any other pharmaceutically acceptable salt form of pramipexole, wherein the formulation is administered to said patient twice daily as a maintenance treatment.
13-18. (canceled)
A kit comprising an immediate release formulation containing an active ingredient selected from the group consisting of pramipexole, pramipexole hydrochloride, pramipexole dihydrochloride and pramipexole dihydrochloride monohydrate, or any other pharmaceutically acceptable salt form of pramipexole, and an instruction to administer the immediate release formulation twice daily.
The kit according to any of claim, wherein the instruction is such that the total every day dosage is applied in two equal amounts.
26-37. (canceled)
39-40. (canceled)
Dependencies are inferred from the claim text.